Tom Yuhao Shi MD PHD

NYU Radiation Oncology Resident | UB MDPHD Alumni

[NYU Radiation Oncology @NYULH_RadOnc]

We are thrilled to announce that we’ve matched with three outstanding applicants this season. Welcome Katherine Meurer, Jenna Rocchetti, and Charvi Shah to NYU Rad Onc! #MatchDay2026

[Adam Grippin @adam_grippin]

🚨Our new paper is out today in Nature! We show that SARS-CoV-2 mRNA vaccines can sensitize tumors to immune checkpoint blockade (ICI) — revealing that clinically available RNA vaccines may act as potent immune modulators. https://t.co/sH13agsz5c

[John Ebos @EbosLab]

We found that the interferon-regulated secretory machinery in tumor cells is ‘rewired’ after acquired resistance to PD-L1 inhibition, altering the immune microenvironment and decreasing the tumor-killing ability of T cells. @RoswellPark #MedTwitter #Oncology #ImmunoOnc

[Tom Yuhao Shi MD PHD @tshi42]

@Srinjoy_Sil @UBuffaloMDPhD @EbosLab @GeneticsRoswell You too Srinjoy! Glad to have already met!

[Tom Yuhao Shi MD PHD @tshi42]

Incredibly excited to have matched at NYU for radiation oncology! Thank you to all my mentors for the support the last 8 years @UBuffaloMDPhD @EbosLab @GeneticsRoswell

[NYU Radiation Oncology @NYULH_RadOnc]

We are absolutely thrilled to have matched Tom (Yuhao) Shi MD,#/PhD and Srinjoy Sil, MD/PhD! Welcome to the NYU RadOnc family and congrats to all who matched today! 🎉 🥳 👏

[Tom Yuhao Shi MD PHD @tshi42]

@sohn_jiho @UTSW_IMResRsrch @UTSWInternalMed @UBuffaloMDPhD Congrats!!

[Nature Reviews Cancer @NatureRevCancer]

NEW content online! Mechanisms driving the immunoregulatory function of cancer cells https://t.co/H4sw0Yrhoz

[Abby Schubach MD @AbbySchubach]

Inspiring lecture by @AasmaShaukatMD regarding the need for colorectal screening. Challenging us to reach a goal of 80%. @monicap_md and I are excited to bring this back to @URMCInternalMed with our QI project to increase CRC screening rates and health equity among our patients.

[John Ebos @EbosLab]

Today is the 3 Minute Thesis Competition hosted by @UBuffalo - Watch at 3pm today when @tshi42 represents @EbosLab @UBuffaloMDPhD @RoswellParkPhD @RoswellPark @3MT.

Please vote!

https://t.co/CNF0F8JCQw

https://t.co/CMgoFyc8sk

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Just in @NEJM :practice changing results in mRCC #kidneycancer 👉Remarkably improved OS, PFS, ORR with Cabozantinib + nivolumab versus sunitinib. QOL was also improved with the combo. Congrats to @DrChoueiri @motzermd @tompowles1 OncoAlert @urotoday https://t.co/KaB22Rn0Te 👇

[DavidBrooksLab @brooks_lab]

Great job Giselle Boukhaled @brooks_lab and Shane Harding @brokendna on our review of the opposing roles of type I interferons in cancer and cancer immunity. There is a lot here and still a whole lot left to learn! Annual Review of Pathology @AnnualReviews https://t.co/AxI2EuMBd6

[Tom Yuhao Shi MD PHD @tshi42]

Very excited to hear about work from the Minn lab today!

[John Ebos @EbosLab]

Today we are virtually hosting @andyjminn
from @PennMedicine
for a seminar in the @GeneticsRoswell
department @RoswellPark. See you at NOON!

[Cancer Research Institute @CancerResearch]

According to a new analysis led by our Clinical Accelerator team and @IQVIA_global, VEGF/VEGFR targeted therapy has emerged as the top combination treatment with PD-1/L1 checkpoint inhibitors in clinical trials in 2020. 📈 #SITC2020 https://t.co/pKbsER3bIc

[Freddy E Escorcia @freddyeescorcia]

Chronic IFN production by tumors = bad !
Acute IFN production = good (for antitumor effect).

Can we mimic IFN KO in cancer cells to induce shift from chronic to acute IFN and cause an anti-tumor effector-like response?

[Cell Reports @CellReports]

PD-L1 reverse signaling in dermal dendritic cells promotes dendritic cell migration required for skin immunity https://t.co/WADKykUcu9

[ESMO - Eur. Oncology @myESMO]

#ESMO20: Lenvatinib plus pembrolizumab show promise in #melanoma after progression on checkpoint inhibitors. LEAP-004 study showed encouraging ORR but survival results difficult to interpret. Read the full Daily Reporter article here https://t.co/8HPoAZWFhk @Rigshospitalet #melsm

[Enrique Grande @drenriquegrande]

⚡️ RT @NatureMedicine: Neoadjuvant #Immunotherapy combination in the NABUCCO trial achieves high response rates in metastatic #bladdercancer patients and provides molecular biomarkers of treatment efficacy https://t.co/qm1zx20Oks #NMEDClinical

[NEJM @NEJM]

Among patients with lung cancer that expressed programmed death ligand 1, the anti–PD-L1 antibody atezolizumab was compared with chemotherapy in a randomized trial.

[Cancer Cell @Cancer_Cell]

Clinical Challenges of Immune Checkpoint Inhibitors https://t.co/wTLMr9mqje

[Neeraj Agarwal, MD, FASCO @neerajaiims]

#ASCO20 Plenary LBA1: “FANTASTIC” news in advanced #bladdercancer Ph 3 trial with “avelumab” front line maintenance Rx improves both OS & PFS.👇New SOC. Congrats @tompowles1 and very proud of dear friend @PGrivasMDPhD -> last author on a @ASCO plenary.👏https://t.co/3U3juwUD1L